Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Apr;138(7):1320-32.
doi: 10.1038/sj.bjp.0705160.

Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery

Affiliations

Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery

W-S Vanessa Ho et al. Br J Pharmacol. 2003 Apr.

Abstract

1. The nonpsychoactive cannabinoid abnormal-cannabidiol (trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) (abn-cbd) produced concentration-dependent relaxation of methoxamine-precontracted rat small mesenteric artery. Endothelial removal reduced abn-cbd potency six-fold without affecting the maximum relaxation. 2. In endothelium-intact vessels, abn-cbd was less potent under 60 mM KCl-induced tone and inhibited by combination of L-N(G)-nitroarginine methyl ester (L-NAME) (nitric oxide synthase inhibitor; 300 micro M), apamin (small conductance Ca(2+)-activated K(+) channels inhibitor; 50 nM) and charybdotoxin (inhibitor of intermediate conductance Ca(2+)-activated K(+) channels and large conductance Ca(2+)-activated K(+) channels BK(Ca); 50 nM). L-NAME alone or in combination with either toxin alone had little effect. 3. In intact vessels, relaxations to abn-cbd were inhibited by SR 141716A (cannabinoid receptor antagonist; 1 or 3 micro M). Concomitant addition of L-NAME, apamin and charybdotoxin had no further effect. Other cannabinoid receptor antagonists either had little (SR 144528; 1 micro M and AM 251; 1 micro M) or no effect (AM 630; 10 micro M and AM 281; 1 micro M). Inhibition of gap junctions, G(i/o) protein coupling and protein kinase A also had no effect. 4. Endothelium-independent relaxation to abn-cbd was unaffected by L-NAME, apamin plus charybdotoxin or capsaicin (10 micro M). Abn-cbd inhibited CaCl(2)-induced contractions in vessels with depleted intracellular Ca(2+) stores and stimulated with methoxamine or KCl. This was insensitive to SR 141716A (3 micro M) but greatly reduced in vessels stimulated with ionomycin (Ca(2+) ionophore; 1 micro M). 5. We conclude that abn-cbd relaxes the rat small mesenteric artery by endothelium-dependent activation of K(+) channels via SR 141716A-sensitive pathways, which do not involve CB(1) and CB(2) receptors. It also causes endothelium-independent, SR 141716A-insensitive, relaxation by inhibiting Ca(2+) entry through voltage-gated Ca(2+) channels.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Concentration–response curves for abnormal-cannabidiol (abn-cbd) induced relaxation of methoxamine-induced tone in rat isolated small mesenteric artery in the presence (n=4) or absence (n=4) of a functional endothelium. Also shown are the effects of the appropriate amounts of vehicle, 0.01–0.3% v v−1 ethanol (n=6). Values are shown as means and vertical lines represent s.e. mean.
Figure 2
Figure 2
(a) Concentration–response curves for abnormal-cannabidiol (abn-cbd) relaxation of methoxamine-induced tone in endothelium-intact rat isolated small mesenteric artery. Relaxation was elicited by abn-cbd alone, and in the presence of 200 nM, 1 μM or 3 μM SR 141716A; n=4 for all. Values are shown as means and vertical lines represent s.e. mean. (b) Original traces of relaxation to abn-cbd in the absence and presence of 3 μM SR 141716A in separate endothelium-intact vessels are shown. Vertical lines denote addition of drugs at the concentration indicated. (c) Concentration–response curves for abn-cbd relaxation of methoxamine-induced tone in endothelium-denuded rat isolated mesenteric artery. Relaxation was elicited by abn-cbd alone, and in the presence of 3 μM SR 141716A n=4 for both. Values are shown as means and vertical lines represent s.e.mean.
Figure 3
Figure 3
Concentration–response curves for abnormal-cannabidiol (abn-cbd) relaxation of methoxamine-induced tone in endothelium-intact rat isolated small mesenteric artery. (a) Relaxation was elicited by abn-cbd alone (n=8), and in the presence of 1 μM AM 251 (n=4) or 1 μM AM 281 (n=4). (b) Relaxation was elicited by abn-cbd alone and in the presence of 1 μM SR 144528; n=6 for both. Values are shown as means and vertical lines represent s.e.mean.
Figure 4
Figure 4
(a) Concentration–response curves for abnormal-cannabidiol (abn-cbd) relaxation of either methoxamine- or KCl-induced tone in rat isolated small mesenteric artery. Abn-cbd relaxed methoxamine-precontracted vessels in the presence (n=7) or absence (n=7) of endothelium. Relaxation to abn-cbd was also observed in 60 mM KCl-precontracted vessels in the presence (n=7) or absence (n=4) of endothelium. Values are shown as means and vertical lines represent s.e. mean. (b) Original recording of the relaxation to abn-cbd in KCl-precontracted, endothelium-intact rat isolated mesenteric artery is shown. Vertical lines denote addition of drugs at the concentration indicated.
Figure 5
Figure 5
Concentration–response curves for abnormal-cannabidiol (abn-cbd) relaxation of methoxamine-induced tone in endothelium-intact rat isolated mesenteric artery. (a) Relaxation was elicited by abn-cbd alone (n=9), or in the presence of either 300 μM L-NAME alone (n=4) or in the presence of 300 μM L-NAME, 50 nM apamin and 50 nM charybdotoxin (n=6). (b) Relaxation was elicited by abn-cbd alone (n=5), or in the presence of 300 μM L-NAME in combination with 50 nM apamin (n=4) or 50 nM apamin and 50 nM iberiotoxin (n=4). Values are shown as means and vertical lines represent s.e.mean.
Figure 6
Figure 6
Concentration–response curves for abnormal-cannabidiol (abn-cbd) relaxation of methoxamine-induced tone in endothelium-intact rat isolated small mesenteric artery. Relaxation was elicited by abn-cbd alone or in the presence of 400 ng ml−1 pertussis toxin (with 2 h preincubation); n=6 for both. Values are shown as means and vertical lines represent s.e.mean.
Figure 7
Figure 7
(a) Concentration–response curves for CaCl2-induced contractions of methoxamine (10 μM)-stimulated rat isolated small mesenteric arteries depleted of intracellular Ca2+ stores with EGTA as described in Methods. All vessels were denuded of endothelium. Contractions to CaCl2 were determined in the absence (n=12) or presence of 3 μM (n=4), 10 μM (n=4) or 30 μM (n=4) abnormal-cannabidiol (abn-cbd) in a given vessel. Control response curves were pooled for clarity. Values are shown as means and vertical lines represent s.e. mean. Statistical comparisons were made by paired t-test at individual concentrations. *P<0.05, **P<0.01, ***P<0.001 indicate significant differences from control values. (b) Shows an original recording of CaCl2-induced contractions in the absence and presence of 10 μM abn-cbd. Vertical lines denote addition of drugs at the concentration indicated. WO denotes wash out with Ca2+-free Krebs–Henseleit solution.
Figure 8
Figure 8
Abnormal-cannabidiol induced relaxation of contractions to 2.5 mM CaCl2 in ionomycin-(1 μM; n=9) or methoxamine-(10 μM; n=4) stimulated rat isolated small mesenteric artery in the absence of extracellular Ca2+. All vessels were denuded of endothelium and depleted of intracellular Ca2+ stores with EGTA as described in Methods. Values are shown as means and vertical lines represent s.e. mean. Statistical comparisons were made by unpaired t-test at individual concentrations. *P<0.05, **P<0.01, ***P<0.001 indicate significant differences from the corresponding values using methoxamine.

Similar articles

Cited by

References

    1. ADAMS M.D., EARNHARDT J.T., MARTIN B.R., HARRIS L.S., DEWEY W.L., RAZDAN R.K. A cannabinoid with cardiovascular activity but no overt behavioural effects. Experientia. 1977;33:1204–1205. - PubMed
    1. AGURELL S., HALLDIN M., LINDGREN J.E., OHLSSON A., WIDMAN M., GILLESPIE H., HOLLISTER L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 1986;38:21–43. - PubMed
    1. BENOWITZ N.L., JONES R.T. Cardiovascular effects of prolonged delta-9-tetrahydro-cannabinol ingestion. Clin. Pharmacol. Ther. 1974;18:287–297. - PubMed
    1. BISOGNO T., HANUS L., DE PETROCELLIS L., TCHILIBON S., PONDE D.E., BRANDI I., MORIELLO A.S., DAVIS J.B., MECHOULAM R., DI MARZO V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001;134:845–852. - PMC - PubMed
    1. BREIVOGEL C.S., GRIFFIN G., DI MARZO V., MARTIN B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001;60:155–163. - PubMed

Publication types

MeSH terms